论文部分内容阅读
目的测定比较系统性红斑狼疮(SLE)患者[尤其是不同病理类型狼疮肾炎(LN)患者]血浆中巨噬细胞衍生趋化因子(MDC)的水平,探讨其作为Th2型免疫反应标志物的变化及意义。方法利用酶联免疫吸附试验(ELISA)检测SLE患者46例(其中经肾活检确定病理分型的LN患者15例)以及类风湿关节炎(RA)患者16例和正常对照16名血浆MDC含量。结果未经治疗的SLE患者与经治患者、RA患者和正常对照组血浆中的MDC含量差异有统计学意义,SLE患者血浆MDC水平与系统性红斑狼疮疾病活动指数(SLEDAI)呈正相关。LN患者血浆中MDC含量与其病理类型存在明显的联系:Ⅱ型和Ⅲ型LN组高于Ⅳ型组。结论MCD可能在估计SLE的活动度和判断LN的类型上具有一定意义。SLE疾病进程与血浆中MDC水平密切相关。
Objective To determine the level of plasma macrophage-derived chemokine (MDC) in patients with systemic lupus erythematosus (SLE), especially in patients with different pathological types of lupus nephritis (LN), and to explore its role as a marker of Th2-type immune response And meaning. Methods The serum levels of MDC in 46 SLE patients (15 with LN confirmed by pathology) and 16 with rheumatoid arthritis (RA) and 16 with normal controls were detected by enzyme-linked immunosorbent assay (ELISA). Results There was significant difference in plasma MDC levels between untreated SLE patients and control patients, RA patients and normal controls. The plasma MDC levels in patients with SLE were positively correlated with the disease activity index of systemic lupus erythematosus (SLEDAI). The level of MDC in plasma of patients with LN was significantly correlated with its pathological types: type Ⅱ and type Ⅲ LN were higher than type Ⅳ. Conclusion MCD may have some significance in estimating the activity of SLE and the type of LN. SLE disease process and plasma MDC levels are closely related.